#ASCO21
ok, now it's mTNBC time: IMpassion130, atezolizumab +nab-paclitaxel vs nab-pac alone. #ASCO21 #bcsm
November 18, 2024 at 1:08 AM
OS benefit even seen in people with an ESR1, PIK3A, and TP53 mutations. Sorry not fast enough on shift-cmmd-4 to capture the PIK3CA slide! #ASCO21 #bcsm
November 18, 2024 at 3:02 AM
presentation was by @MCristofanill #ASCO21 #bcsm
November 18, 2024 at 3:02 AM
and another plain language summary (I may just swoon with joy) #ASCO21 #bcsm #PlainLanguage
November 18, 2024 at 3:01 AM
I'd like to pose this question and it's corollary, is there a future path to determine receptors via liquid bx, to #breast oncs @hoperugo @ErikaHamilton9 @DrSGraff @tmprowell @stolaney1 @FAndreMD @DrEricWiner @DrLisaCarey @StoverLab @nlinmd
#ASCO21 #bcsm
#MetastaticBreastCancer changes with exposure to treatment. Luminal A (ER+, HER2-, ki67 low, PR high) can become more aggressive Luminal B (ER+, HER2- with ki67 high OR PR low OR ER+, HER2+). Should we all have a tissue biopsy at progression to determine this? #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
Poster is "CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study", Pacual et al, abstract 1014. CCNE1 is the gene Cyclin E1 which activates CDK2. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
With 6 years of follow up, OS improvement of Palbociclib/fulvestrant vs fulvestrant alone is maintained EXCEPT in people with prior IV chemo. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
like all the other CDK 4/6 inhibitors, improvement in PFS is noted (but it's not 10 mo like most of the others) AEs look closest to Palbociclib, with decr WBC. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
no improvement in PFS with venetoclax, a BCL2 inhibitor, and more AEs. No clinical benefit even in the BCL2 high groups, expect *maybe* in people without a PIK3CA mutation. Negative results are still important. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
and here are the AEs. Instead of "tolerable" Dr Shao used "manageable", which is better #WordsMatter #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
In the phase 2, stable disease was seen in 43% of people and a partial response in 17%. Those with the Y537S ESR1 mutation had the highest clinical benefit rate, although those with D538G also showed some benefit. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
RC48-ADC (sounds like something from Star Wars, maybe R2D2's cousin?) has shown efficacy in HER2low as well as HER2+ (abstract 1022 Wang et al). Trial is open in China, global trial may be on the way. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
Can we stay #NotDeadYet for a meaningful amount of time on alpelisib? Abstract 1054 looks at data from SOLAR1 and X2101 trials and concludes yes - about 30% of people in SOLAR1 and 13% in X2101 had a PFS > 18 months. All had endocrine resistant disease. #ASCO21 #bcsm
November 18, 2024 at 2:18 AM
pretty impressive response rates for this triplet combo - but it requires IV chemo 3 weeks out of 4. And what about AEs? #ASCO21 #bcsm
November 18, 2024 at 1:36 AM
In the phase 1 over half the #clinicaltrial heros had had 3+ prior LOT. The most unusual AE was a low heart rate; the others were our old "friends" nausea, diarrhea, fatigue, hot flashes. (where's the drug where the AE are glowing skin and increased energy?) #ASCO21 #bcsm
November 18, 2024 at 1:36 AM
The idea of HER2low may also apply to those with TNBC, again opening up new treatment options with HER2 directed ADCs (antibody to HER2 coupled with a cancer cell killing agent. Abstract e13046 Yang et al showed 38% of #metastatic TNBC was HER2low. #ASCO21 #bcsm
November 18, 2024 at 1:36 AM
And a huge THANK YOU for this plain language summary/infographic, accessed via the QR code on the poster!! #ASCO21 #bcsm
November 18, 2024 at 1:36 AM
It's Saturday and what am I doing? Reading #ASCO21 abstracts! (granted, it's snowing now so outdoor activities aren't very appealing....) #HowToSayYouHaveCancerWithoutSayingYouHaveCancer
November 18, 2024 at 1:09 AM
Do you know what I hate the most about IRL meetings? The door drops of brochures I throw right in the 🗑. Do you know what’s even worse? Having the same 💩 mailed for a virtual meeting. How about banning this in the future @ASCO? #ASCO21
November 18, 2024 at 1:09 AM
#MetastaticBreastCancer changes with exposure to treatment. Luminal A (ER+, HER2-, ki67 low, PR high) can become more aggressive Luminal B (ER+, HER2- with ki67 high OR PR low OR ER+, HER2+). Should we all have a tissue biopsy at progression to determine this? #ASCO21 #bcsm
November 18, 2024 at 1:09 AM
Biomarkers to predict whether our treatments are going to work or not is something people with #metastaticbreastcancer are dying for (literally). Will checking for CCNE1 expression be something that's done in the future, before prescribing Palbociclib? #ASCO21 #bcsm
November 18, 2024 at 1:09 AM
Had to take a quick break from #ASCO21 to water our dying lawn - our HOA banned irrigation as 2/3 of our wells are contaminated with uranium. We own another property on its own well and my husband trucks in 2 575 gal tanks every day. PITA but at least we get rainbows!
November 18, 2024 at 1:09 AM
Looking forward this session of oral abstracts on #MetastaticBreastCancer #ASCO21 #bcsm
November 18, 2024 at 1:09 AM
first up: Update on OS in PALOMA3. The people in this trial had progressed on prior endocrine therapy and could have had 1 prior line of chemo. #ASCO21 #bcsm
November 18, 2024 at 1:09 AM
Now up MONALESSA3, ribo/fulv vs fulv alone, update by Dr Dennis Slamon #ASCO21 #bcsm
November 18, 2024 at 1:09 AM